Wolfe Research analyst Mike Polark initiated coverage of Beta Bionics (BBNX) with an Outperform rating and $20 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Positive Developments and Strategic Advancements Drive Buy Rating for Beta Bionics, Inc.
- Beta Bionics Q1 2025 Earnings: Strong Growth and Optimism
- Strong Performance and Growth Potential: Buy Rating for Beta Bionics, Inc.
- Beta Bionics price target lowered to $15 from $20 at Baird
- Positive Developments and Strong Financial Performance Drive Buy Rating for Beta Bionics, Inc.